Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp in Refractory or Intolerant Fungal Diseases (FURI)
NCT03059992Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Apr 2017
- Primary completion
- Aug 2023
- Modality
- Allosteric Modulators
- Countries
- 8
01
Overview
A Phase 3 trial of ibrexafungerp in invasive candidiasis, chronic mucocutaneous candidiasis (CMC), coccidioidomycosis, histoplasmosis, blastomycosis, sponsored by SCYNEXIS, Inc.. Started Apr 2017; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
invasive candidiasischronic mucocutaneous candidiasis (CMC)coccidioidomycosishistoplasmosisblastomycosis
Beyond the preview
Go deeper on NCT03059992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059992.